Expression Characteristics of PDZRN3 in Endometrial Cancer and Its Bioinformatics Evaluation

HOU Liheng; FENG Zhiqiang; REN Lili; LIU Chao

doi:10.3969/j.issn.2096-305X.2025.05.001

Abstract：Objective To evaluate the expression characteristics of E3 ubiquitin ligase(PDZ Domain Containing Ring Finger 3,PDZRN3)in endometrial cancer using bioinformatics.Methods The expression differences of PDZRN3 in endometrial cancer tissues and normal endometrial tissues were analyzed using TIMER2 and Xiantao Academic( on the clinical information of endometrial cancer patients from the TCGA database,baseline data tables were created using the stats package in R software.The clinical stages and pathological grades were analyzed using the stats,car,and ggplot2 packages.Kaplan-Meier survival curves were plotted using the survival and survminer packages.The COX proportional hazards model was analyzed using the survivalR package,and COX regression analysis tables were created.Diagnostic ROC curves and nomogram models were generated using the pROC and survival packages.In vitro,endometrial cancer cell lines AN3CA and Ishikawa were cultured,and the protein expression of PDZRN3 in these two cell lines was detected by Western Blot.Results TIMER2 database and Xiantao academic analysis showed that PDZRN3 was lowly expressed in endometrial cancer tissues(P＜0.05).TCGA database indicated that the expression of PDZRN3 was significantly correlated with clinical stage,histological grade and histological type(P＜0.05).Endometrial cancer patients with higher PDZRN3 expression had higher overall survival(OS),disease-specific survival(DSS)and progression-free interval(PFI),while those with lower PDZRN3 expression had lower OS,DSS and PFI.Both univariate and multivariate COX regression analyses demonstrated that the expression of PDZRN3,age,clinical stage,and pathological grade in endometrial cancer patients were risk factors affecting prognosis(P＜0.05).The ROC curve results indicated that the expression of PDZRN3 could help distinguish tumor tissues from non-tumor tissues(AUC:0.865),and the nomogram model could be used to predict the 1-year,3-year,and 5-year survival probabilities of clinical patients.Western Blot results showed that PDZRN3 was highly expressed in the endometrial cancer cell line AN3CA(P＜0.01),and was lowly expressed in the endometrial cancer cell line Ishikawa(P＜0.01).Conclusion PDZRN3,as a highly promising biomarker,is expected to play a significant role in the stratification,prognosis assessment,and treatment intervention of patients with endometrial cancer.